Search Results - "Dummer R"

1621P First-line pembrolizumab alone or with investigational agents for advanced melanoma: Updated results from the phase I/II KEYMAKER-U02 substudy 02B.

Authors: Gogas, H. Dummer, R. Shapira-Frommer, R. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS962-S963. 2p.

Theoretical and practical implication of the bidirectional reflectance of spacecraft surfaces.

Authors: Neu, J. T. Dummer, R. S.

Source: AIAA Journal; March 1969, Vol. 7, p484-491, 8p

Melanomtherapie -- ein Paradigma für die «personalized medicine».

Alternate Title: Therapeutic approaches in Melanoma -- a Paradigm for Personalized Medicine.

Authors: Dummer, R. Goldinger, S. Rinderknecht, J. et al.

Source: Praxis (1661-8157). 8/1/2012, Vol. 101 Issue 15, p955-959. 5p.

Die Rolle der Chirurgie in der Behandlung des kutanen Melanoms.

Alternate Title: The Role of Surgery in the Treatment of Cutaneous Melanoma.

Authors: Guggenheim, M. Dummer, R. Giovanoli, P.

Source: Praxis (1661-8157). 7/20/2011, Vol. 100 Issue 15, p911-916. 6p.

The influence of sentinel lymph node tumour burden on additional lymph node involvement and disease-free survival in cutaneous melanoma--a retrospective analysis of 392 cases.

Authors: Guggenheim, M. Dummer, R. Jung, F. J. et al.

Source: British Journal of Cancer. 6/17/2008, Vol. 98 Issue 12, p1922-1928. 7p. 5 Charts, 1 Graph.

Melanoma Vaccines in Development: Looking to the Future.

Authors: Dummer, R. Nestle, F.O.

Source: BioDrugs. 2000, Vol. 13 Issue 4, p227-231. 5p.

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.

Authors: Dummer, R. Hauschild, A. Santinami, M. et al.

Source: New England Journal of Medicine. 9/17/2020, Vol. 383 Issue 12, p1139-1148. 10p.

Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion.

Authors: Dummer, R. Ascierto, P.A. Basset‐Seguin, N. et al.

Source: Journal of the European Academy of Dermatology & Venereology. Sep2020, Vol. 34 Issue 9, p1944-1956. 13p.

1083P KEYMAKER 02B: A randomized trial of pembrolizumab (pembro) alone or with investigational agents as first-line treatment for advanced melanoma.

Authors: Dummer, R. Shapira, R. Pigozzo, J. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS717-S718. 2p.

Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study.

Authors: Dummer, R. Guminksi, A. Gutzmer, R. et al.

Source: British Journal of Dermatology. Jun2020, Vol. 182 Issue 6, p1369-1378. 10p.

Modified HSTs power all-hydraulic marine crane.

Authors: Matthews, R. W. Dummer, R. E.

Source: Hydraulics & Pneumatics; May 1977, Vol. 30, p71-74, 4p

Light‐based therapies and scar sarcoidosis.

Authors: Walther, M. Dummer, R. Imhof, L.

Source: Journal of the European Academy of Dermatology & Venereology. Dec2020, Vol. 34 Issue 12, pe805-e807. 3p.

1071TiP Phase I study of the investigational CD228 x 4-1BB costimulatory antibody anticalin bispecific SGN-BB228 (PF-08046049) in advanced melanoma and other solid tumors.

Authors: Dummer, R. Daud, A. Eigentler, T.K. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS709-S709. 1p.

1113P COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (enco) + binimetinib (bini) vs vemurafenib (vemu) or enco in patients (pts) with BRAF V600–mutant melanoma.

Authors: Schadendorf, D. Dummer, R. Flaherty, K.T. et al.

Source: Annals of Oncology. 2023 Supplement 2, Vol. 34, pS670-S671. 2p.

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors: Dummer, R. Hauschild, A. Lindenblatt, N. et al.

Source: Annals of Oncology. 2015 Suppl. 5, Vol. 26, pv126-v132. 7p. 3 Charts.

Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous t-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome).

Authors: Dummer, R. Duvic, M. Scarisbrick, J. et al.

Source: Annals of Oncology. Sep2014, Vol. 25 Issue 9, p1807-1812. 6p.

1180TiP Randomized phase II trial (PORTSIDE) evaluating encorafenib (enco) and binimetinib (bini) plus pembrolizumab (pembro) versus nivolumab (nivo) and ipilimumab (ipi) for the treatment of advanced BRAF-mutant melanoma.

Authors: Schadendorf, D. Dummer, R. Ribas, A. et al.

Source: Annals of Oncology. 2023 Supplement 2, Vol. 34, pS700-S700. 1p.

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.

Authors: Eggermont AM Suciu S Santinami M et al.

Source: Lancet. 7/12/2008, Vol. 372 Issue 9633, p117-126. 10p.

1041MO 5-year update on COLUMBUS: A randomized phase III trial of encorafenib (enco) + binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma.

Authors: Dummer, R. Flaherty, K.T. Robert, C. et al.

Source: Annals of Oncology. 2021 Supplement 5, Vol. 32, pS872-S873. 2p.

Maintenance therapy in cutaneous T-cell lymphoma: Who, when, what?

Authors: Dummer, R. Assaf, C. Bagot, M. et al.

Source: European Journal of Cancer. Nov2007, Vol. 43 Issue 16, p2321-2329. 9p.